| Name | doxycycline | 
|---|---|
| Synonyms | 
                                
                                Monodox
                                
                                
                                 azudoxat Doxycen MFCD02682958 gs-3065 (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[Amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydro-1,3,12(2H,4H,5H)-tetracenetrione 1,3,12(2H,4H,5H)-Naphthacenetrione, 2-(aminohydroxymethylene)-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-5,10,11,12a-tetrahydroxy-6-methyl-, (2Z,4S,4aR,5S,5aR,6R,12aS)- Ronaxan doxocycline doryx Unidox (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[Amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione doxitard Doxycycline spanor Doxinyl EINECS 209-271-1  | 
                        
| Description | Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. | 
|---|---|
| Related Catalog | |
| In Vitro | Doxycycline affects growth of glioma cells only under high concentrations[2]. Doxycycline decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells[2]. Cell Proliferation Assay[2] Cell Line: LNT-229, G55, and U343 glioma cells Concentration: 0.01, 0.1, 1, or 10 µg/mL Incubation Time: 4 days Result: Affected growth of glioma cells only under high concentrations. Western Blot Analysis[2] Cell Line: SVG cells Concentration: 0.01, 0.1, 1, or 10 µg/mL Incubation Time: 24 hours Result: Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher. | 
| In Vivo | Doxycycline (oral; 200 or 800 mg/kg/day; for 3 months) reduces active MMP-9 in untreated HT mice in a dose-dependent manner[1]. Animal Model: 6-month-old female Heterozygous Col3a1-deficient (HT) mice[1] Dosage: 200 or 800 mg/kg Administration: Oral; per day; for 3 months Result: Reduced active MMP-9 in a dose-dependent manner. | 
| References | 
| Density | 1.6±0.1 g/cm3 | 
|---|---|
| Boiling Point | 685.2±55.0 °C at 760 mmHg | 
| Melting Point | 206-209ºC | 
| Molecular Formula | C22H24N2O8 | 
| Molecular Weight | 444.435 | 
| Flash Point | 368.2±31.5 °C | 
| Exact Mass | 444.153259 | 
| PSA | 181.62000 | 
| LogP | 1.36 | 
| Vapour Pressure | 0.0±2.2 mmHg at 25°C | 
| Index of Refraction | 1.737 | 
| Storage condition | 2-8C | 
                                CHEMICAL IDENTIFICATION
 
 
 
 
 
 
 
 HEALTH HAZARD DATAACUTE TOXICITY DATA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MUTATION DATA
 
 
 
  | 
                        
| HS Code | 3004909090 | 
|---|
| 
                                
                                
                                
                                
                                
                                
                                 ~98%  
                                    564-25-0  | 
                        
| Literature: Tetrahedron Letters, , vol. 34, # 9 p. 1471 - 1474 | 
| 
                                
                                
                                
                                
                                
                                
                                 ~%  
                                    564-25-0  | 
                        
| Literature: CrystEngComm, , vol. 14, # 7 p. 2532 - 2540 | 
| Precursor 2 | |
|---|---|
| DownStream 2 | |
| HS Code | 3004909090 | 
|---|